First National Bank of Omaha Acquires New Holdings in Becton, Dickinson and Company $BDX

First National Bank of Omaha acquired a new stake in Becton, Dickinson and Company (NYSE:BDX) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 12,032 shares of the medical instruments supplier’s stock, valued at approximately $2,252,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Crestwood Advisors Group LLC bought a new stake in shares of Becton, Dickinson and Company in the third quarter worth about $261,000. NEOS Investment Management LLC lifted its holdings in shares of Becton, Dickinson and Company by 44.0% during the 3rd quarter. NEOS Investment Management LLC now owns 39,656 shares of the medical instruments supplier’s stock valued at $7,422,000 after purchasing an additional 12,113 shares in the last quarter. Heartland Advisors Inc. grew its position in shares of Becton, Dickinson and Company by 23.2% in the 3rd quarter. Heartland Advisors Inc. now owns 89,168 shares of the medical instruments supplier’s stock valued at $16,690,000 after purchasing an additional 16,805 shares during the period. Rothschild Investment LLC increased its stake in Becton, Dickinson and Company by 19.2% during the 3rd quarter. Rothschild Investment LLC now owns 868 shares of the medical instruments supplier’s stock worth $162,000 after purchasing an additional 140 shares in the last quarter. Finally, M&G PLC raised its holdings in Becton, Dickinson and Company by 4.9% during the 3rd quarter. M&G PLC now owns 935,480 shares of the medical instruments supplier’s stock worth $174,935,000 after buying an additional 43,404 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Up 3.1%

BDX stock opened at $182.82 on Thursday. The company has a market cap of $52.06 billion, a price-to-earnings ratio of 29.82, a P/E/G ratio of 2.32 and a beta of 0.25. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $185.02. The business has a 50 day moving average price of $198.01 and a two-hundred day moving average price of $192.26. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. The firm had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same quarter last year, the company posted $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has approved a share repurchase plan on Tuesday, January 27th that permits the company to repurchase $10.00 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is 68.52%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the transaction, the director directly owned 36,763 shares of the company’s stock, valued at $6,713,291.43. The trade was a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares in the company, valued at $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 3,416 shares of company stock worth $675,557. 0.40% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on BDX. JPMorgan Chase & Co. reduced their price target on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a report on Tuesday, February 10th. Jefferies Financial Group cut their price objective on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. Stifel Nicolaus increased their target price on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. TD Cowen boosted their price target on Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a report on Wednesday, February 11th. Finally, Citigroup decreased their price objective on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Five investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Hold” and a consensus target price of $195.46.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.